Literature DB >> 17006758

Possible mechanisms of neurodegeneration in schizophrenia.

Iván Pérez-Neri1, Jesús Ramírez-Bermúdez, Sergio Montes, Camilo Ríos.   

Abstract

Brain morphological alterations in schizophrenic patients have led to the neurodevelopmental hypothesis of schizophrenia. On the other hand, a progressive neurodegenerative process has also been suggested and some follow-up studies have shown progressive morphological changes in schizophrenic patients. Several neurotransmitter systems have been suggested to be involved in this disorder and some of them could lead to neuronal death under certain conditions. This review discusses some of the biochemical pathways that could lead to neurodegeneration in schizophrenia showing that neuronal death may have a role in the etiology or natural course of this disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17006758     DOI: 10.1007/s11064-006-9162-3

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  241 in total

Review 1.  Ageing of the brain.

Authors:  Brian H Anderton
Journal:  Mech Ageing Dev       Date:  2002-04       Impact factor: 5.432

Review 2.  Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes.

Authors:  William R Perlman; Cynthia Shannon Weickert; Mayada Akil; Joel E Kleinman
Journal:  J Psychiatry Neurosci       Date:  2004-07       Impact factor: 6.186

Review 3.  Catecholamine metabolism: basic aspects and clinical significance.

Authors:  I J Kopin
Journal:  Pharmacol Rev       Date:  1985-12       Impact factor: 25.468

4.  The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat.

Authors:  B Alessandri; E Tsuchida; R M Bullock
Journal:  Brain Res       Date:  1999-10-23       Impact factor: 3.252

5.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

Authors:  G Walkinshaw; C M Waters
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

6.  A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis.

Authors:  R Damadzic; L B Bigelow; L S Krimer; D A Goldenson; R C Saunders; J E Kleinman; M M Herman
Journal:  Brain Res Bull       Date:  2001-07-15       Impact factor: 4.077

7.  [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia.

Authors:  P W Burnet; S L Eastwood; P J Harrison
Journal:  Neurochem Int       Date:  1997-06       Impact factor: 3.921

8.  Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia.

Authors:  L F Jarskog; J H Gilmore; E S Selinger; J A Lieberman
Journal:  Biol Psychiatry       Date:  2000-10-01       Impact factor: 13.382

9.  Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia.

Authors:  Naoya Nishioka; Steven E Arnold
Journal:  Am J Geriatr Psychiatry       Date:  2004 Mar-Apr       Impact factor: 4.105

10.  Bcl-2 inhibits the mitochondrial release of an apoptogenic protease.

Authors:  S A Susin; N Zamzami; M Castedo; T Hirsch; P Marchetti; A Macho; E Daugas; M Geuskens; G Kroemer
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

View more
  16 in total

1.  Carnosic Acid Suppresses the H2O2-Induced Mitochondria-Related Bioenergetics Disturbances and Redox Impairment in SH-SY5Y Cells: Role for Nrf2.

Authors:  Marcos Roberto de Oliveira; Gustavo da Costa Ferreira; Alessandra Peres; Simone Morelo Dal Bosco
Journal:  Mol Neurobiol       Date:  2017-01-13       Impact factor: 5.590

Review 2.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

3.  The Evaluation of Folic Acid-Deficient or Folic Acid-Supplemented Diet in the Gestational Phase of Female Rats and in Their Adult Offspring Subjected to an Animal Model of Schizophrenia.

Authors:  L Canever; C S V Alves; G Mastella; L Damázio; J V Polla; S Citadin; L A De Luca; A S Barcellos; M L Garcez; J Quevedo; J Budni; A I Zugno
Journal:  Mol Neurobiol       Date:  2017-03-24       Impact factor: 5.590

Review 4.  Adaptive Immunity in Schizophrenia: Functional Implications of T Cells in the Etiology, Course and Treatment.

Authors:  Monojit Debnath
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-11       Impact factor: 4.147

5.  Homozygous Deletion of Glutathione Peroxidase 1 and Aldehyde Dehydrogenase 1a1 Genes Is Not Associated with Schizophrenia-Like Behavior in Mice.

Authors:  Xiang Bai; Elizabeth Fermandez; Georgianna Gould; Randy Strong
Journal:  J Biochem Pharmacol Res       Date:  2013-12-01

6.  Oxidative stress in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

Review 7.  Psychiatric Disorders and Polyphenols: Can They Be Helpful in Therapy?

Authors:  Jana Trebatická; Zdeňka Ďuračková
Journal:  Oxid Med Cell Longev       Date:  2015-06-09       Impact factor: 6.543

8.  Systems biology, bioinformatics, and biomarkers in neuropsychiatry.

Authors:  Ali Alawieh; Fadi A Zaraket; Jian-Liang Li; Stefania Mondello; Amaly Nokkari; Mahdi Razafsha; Bilal Fadlallah; Rose-Mary Boustany; Firas H Kobeissy
Journal:  Front Neurosci       Date:  2012-12-24       Impact factor: 4.677

9.  Nerve growth factor and its receptor in schizophrenia.

Authors:  Roksana Zakharyan; Sofi Atshemyan; Anaida Gevorgyan; Anna Boyajyan
Journal:  BBA Clin       Date:  2014-05-20

10.  Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia.

Authors:  Rose-Marie Karlsson; Kohichi Tanaka; Lisa M Saksida; Timothy J Bussey; Markus Heilig; Andrew Holmes
Journal:  Neuropsychopharmacology       Date:  2008-12-10       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.